HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Late Gadolinium Enhancement Cardiovascular Magnetic Resonance Assessment of Substrate for Ventricular Tachycardia With Hemodynamic Compromise.

Abstract
Background: The majority of data regarding tissue substrate for post myocardial infarction (MI) VT has been collected during hemodynamically tolerated VT, which may be distinct from the substrate responsible for VT with hemodynamic compromise (VT-HC). This study aimed to characterize tissue at diastolic locations of VT-HC in a porcine model. Methods: Late Gadolinium Enhancement (LGE) cardiovascular magnetic resonance (CMR) imaging was performed in eight pigs with healed antero-septal infarcts. Seven pigs underwent electrophysiology study with venous arterial-extra corporeal membrane oxygenation (VA-ECMO) support. Tissue thickness, scar and heterogeneous tissue (HT) transmurality were calculated at the location of the diastolic electrograms of mapped VT-HC. Results: Diastolic locations had median scar transmurality of 33.1% and a median HT transmurality 7.6%. Diastolic activation was found within areas of non-transmural scar in 80.1% of cases. Tissue activated during the diastolic component of VT circuits was thinner than healthy tissue (median thickness: 5.5 mm vs. 8.2 mm healthy tissue, p < 0.0001) and closer to HT (median distance diastolic tissue: 2.8 mm vs. 11.4 mm healthy tissue, p < 0.0001). Non-scarred regions with diastolic activation were closer to steep gradients in thickness than non-scarred locations with normal EGMs (diastolic locations distance = 1.19 mm vs. 9.67 mm for non-diastolic locations, p < 0.0001). Sites activated late in diastole were closest to steep gradients in tissue thickness. Conclusions: Non-transmural scar, mildly decreased tissue thickness, and steep gradients in tissue thickness represent the structural characteristics of the diastolic component of reentrant circuits in VT-HC in this porcine model and could form the basis for imaging criteria to define ablation targets in future trials.
AuthorsJohn Whitaker, Radhouene Neji, Steven Kim, Adam Connolly, Thierry Aubriot, Justo Juliá Calvo, Rashed Karim, Caroline H Roney, Brendan Murfin, Carla Richardson, Stephen Morgan, Tevfik F Ismail, James Harrison, Judith de Vos, Maurice C G Aalders, Steven E Williams, Rahul Mukherjee, Louisa O'Neill, Henry Chubb, Cory Tschabrunn, Elad Anter, Luigi Camporota, Steven Niederer, Sébastien Roujol, Martin J Bishop, Matthew Wright, John Silberbauer, Reza Razavi, Mark O'Neill
JournalFrontiers in cardiovascular medicine (Front Cardiovasc Med) Vol. 8 Pg. 744779 ( 2021) ISSN: 2297-055X [Print] Switzerland
PMID34765656 (Publication Type: Journal Article)
CopyrightCopyright © 2021 Whitaker, Neji, Kim, Connolly, Aubriot, Calvo, Karim, Roney, Murfin, Richardson, Morgan, Ismail, Harrison, de Vos, Aalders, Williams, Mukherjee, O'Neill, Chubb, Tschabrunn, Anter, Camporota, Niederer, Roujol, Bishop, Wright, Silberbauer, Razavi and O'Neill.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: